We are investigating the safety and effectiveness of a new treatment for patients with triple negative metastatic breast cancer whose disease has worsened after prior therapies. This study will help us learn more about how well this treatment works and its safety profile.
Health conditions and diseases that the clinical trial is designed to study and treat.
Triple Negative Metastatic Breast Cancer (TNBC) is a type of breast cancer that lacks three common receptors: estrogen, progesterone, and the HER2 protein. This makes it more challenging to treat, often leading to aggressive disease progression.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
